Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer

BMC Gastroenterology

Table 5 Potential combined ATX and/or LPA with CA19-9 biomarkers

Biomarkers	AUROC ± SEM	95% CI	p value
TS1 + TS2 vs. HVs
CA19-9	0.837 ± 0.0423	0.673–0.939
CA19-9 + ATX	0.953 ± 0.0309	0.823–0.996	0.0268*
CA19-9 + ATX + LPA	0.983 ± 0.016	0.970–0.999	0.0012*
TS1 + TS2 vs. BPDs
CA19-9	0.821 ± 0.065	0.758–0.972
CA19-9 + ATX	0.926 ± 0.041	0.849–0.993	0.0381*
CA19-9 + ATX + LPA	0.973 ± 0.023	0.921–0.999	0.0090*
TS3 + TS4 vs. HVs
CA19-9	0.836 ± 0.064	0.691–0.931
CA19-9 + ATX	0.898 ± 0.0516	0.767–0.969	0.4508
CA19-9 + ATX + LPA	0.991 ± 0.0917	0.902–0.999	0.1657
TS3 + TS4 vs. BPDs
CA19-9	0.835 ± 0.094	0.714–0.951
CA19-9 + ATX	0.881 ± 0.066	0.827–0.992	0.279
CA19-9 + ATX + LPA	0.942 ± 0.078	0.913–0.999	0.136

HVs, healthy volunteers; BPDs, benign pancreatic diseases; TS, tumor stage; SEM, standard error of the mean; AUROC, Areas Under the ROC Curves
^*Depicts significance at p value < 0.05

ISSN: 1471-230X